Physician profile
Beth Porter
NPI 1205338613
$5,952.83
in general payments reported to CMS, 2019-2025
27 companies · $1,635 in 2025
The $1,635 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,301 · 2022: $659 · 2023: $1,351 · 2024: $1,008 · 2025: $1,635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,907 · Education: $86.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,907.12 |
| Education | $86.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,218.11 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $464.93 | 2022-2025 | Entyvio, Eohilia |
| Pfizer INC. | $433.05 | 2021-2025 | |
| Gilead Sciences, INC. | $410.58 | 2021-2025 | Epclusa |
| Janssen Biotech, INC. | $375.55 | 2021-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $279.29 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $278.05 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $222.27 | 2024-2025 | Vowst, Zenpep |
| Celgene Corporation | $182.44 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $155.67 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $128.42 | 2021 | |
| Lilly USA, LLC | $122.84 | 2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $103.94 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $90.42 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.27 | 2023-2024 | Cyltezo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $75.16 | 2021-2025 | Ocaliva |
| Sandoz INC. | $57.20 | 2024 | Hyrimoz |
| Braintree Laboratories, INC. | $50.69 | 2021-2025 | Sutab, Suflave |
| Amgen INC. | $46.89 | 2022-2023 | Amjevita, Avsola |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.17 | 2025 | Xifaxan |
| Intuitive Surgical, INC. | $31.61 | 2022 | |
| Novo Nordisk INC | $26.43 | 2025 | Wegovy |
| Immunitybio, INC. | $23.84 | 2025 | |
| Ferring Pharmaceuticals INC. | $19.99 | 2023 | Rebyota |
| Redhill Biopharma INC. | $14.67 | 2021 | |
| Daiichi Sankyo INC. | $14.11 | 2021 | |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.